Dexmethylphenidate | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Dexmethylphenidate
US Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Dexmethylphenidate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

12 API Suppliers, 8 USDMF, 9 NDC API, 7 Listed Suppliers, $ API Reference Price

12 API Suppliers
8 USDMF
9 NDC API
7 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

32 Drugs in Development

32 Drugs in Development

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

120 FDF Dossiers, 112 FDA Orange Book, 8 Europe

120 FDF Dossiers
112 FDA Orange Book
8 Europe

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG, TABLET;ORAL - 2.5MG, TABLET;ORAL - 5MG, CAPSULE, EXTENDED RELEASE;ORAL - 10MG, CAPSULE, EXTENDED RELEASE;ORAL - 15MG, CAPSULE, EXTENDED RELEASE;ORAL - 20MG, CAPSULE, EXTENDED RELEASE;ORAL - 25MG, CAPSULE, EXTENDED RELEASE;ORAL - 30MG, CAPSULE, EXTENDED RELEASE;ORAL - 35MG, CAPSULE, EXTENDED RELEASE;ORAL - 40MG, CAPSULE, EXTENDED RELEASE;ORAL - 5MG

TABLET;ORAL - 10MG
TABLET;ORAL - 2.5MG
TABLET;ORAL - 5MG
CAPSULE, EXTENDED RELEASE;ORAL - 10MG
CAPSULE, EXTENDED RELEASE;ORAL - 15MG
CAPSULE, EXTENDED RELEASE;ORAL - 20MG
CAPSULE, EXTENDED RELEASE;ORAL - 25MG
CAPSULE, EXTENDED RELEASE;ORAL - 30MG
CAPSULE, EXTENDED RELEASE;ORAL - 35MG
CAPSULE, EXTENDED RELEASE;ORAL - 40MG
CAPSULE, EXTENDED RELEASE;ORAL - 5MG

RELATED EXCIPIENT COMPANIES

10 Evonik, 4 SPI Pharma, 2 Seqens, 8 DKSH, 4 Faran Shimi Pharmaceutical, 4 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 4 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 18 BASF, 2 Clariant, 21 Corel Pharma Chem, 6 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 7 Gangwal Chemicals, 13 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 36 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 12 Microlex e.U, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 18 Roquette, 8 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 5 The Dow Chemical Company, 2 Valens Pharmachem, 3 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

71 Coating Systems & Additives, 68 Fillers, Diluents & Binders, 50 Controlled & Modified Release, 26 Thickeners and Stabilizers, 19 Film Formers & Plasticizers, 19 Granulation, 19 Taste Masking, 19 Solubilizers, 19 Direct Compression, 17 Lubricants & Glidants, 17 Disintegrants & Superdisintegrants, 15 Topical, 11 Co-Processed Excipients, 9 Parenteral, 9 Empty Capsules, 6 Chewable & Orodispersible Aids, 6 Emulsifying Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 4 API Stability Enhancers, 3 Rheology Modifiers

71 Coating Systems & Additives
68 Fillers, Diluents & Binders
50 Controlled & Modified Release
26 Thickeners and Stabilizers
19 Film Formers & Plasticizers
19 Granulation
19 Taste Masking
19 Solubilizers
19 Direct Compression
17 Lubricants & Glidants
17 Disintegrants & Superdisintegrants
15 Topical
11 Co-Processed Excipients
9 Parenteral
9 Empty Capsules
6 Chewable & Orodispersible Aids
6 Emulsifying Agents
5 Coloring Agents
4 Vegetarian Capsules
4 Surfactant & Foaming Agents
4 API Stability Enhancers
3 Rheology Modifiers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 41 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
41 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 36 Finished Drug Prices, 6 Annual Reports

4 US Medicaid Prescriptions
36 Finished Drug Prices
6 Annual Reports

MARKET PLACE

2 APIs

2 APIs

PATENTS & EXCLUSIVITIES

18 US Patents, 3 US Exclusivities, 6 Health Canada Patents

18 US Patents
3 US Exclusivities
6 Health Canada Patents

$ API Ref.Price (USD/KG) : 6,777 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

18 All

01 18COMMAVE THERAP

filter Patent Number Reset all filters

18 All

01 39079928

02 310584112

03 310584113

04 310759778

05 310858341

06 310954213

filter API Patent Reset all filters

18 All

01 3Y

02 15Blank

filter FDF Patent Reset all filters

18 All

01 12Y

02 6Blank

filter Expiration Date Reset all filters

18 All

01 32032-07-27

02 152037-12-09

Product Main Page

01

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10858341

Drug Substance Claim :

Drug Product Claim :

Application Number : 212994

Patent Use Code : U-3094

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10954213

Drug Substance Claim :

Drug Product Claim :

Application Number : 212994

Patent Use Code : U-3094

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10858341

Drug Substance Claim :

Drug Product Claim :

Application Number : 212994

Patent Use Code : U-3094

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10954213

Drug Substance Claim :

Drug Product Claim :

Application Number : 212994

Patent Use Code : U-3094

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10954213

Drug Substance Claim :

Drug Product Claim :

Application Number : 212994

Patent Use Code : U-3094

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10858341

Drug Substance Claim :

Drug Product Claim :

Application Number : 212994

Patent Use Code : U-3094

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10584112

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212994

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10584112

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 212994

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10584113

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212994

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

COMMAVE THERAP

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

BioAsia

Not Confirmed

COMMAVE THERAP

Country

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2037-12-09

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

US Patent Number : 10759778

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 212994

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2037-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!